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Abstract: Venous disorders have a high prevalence and require approximately 1% of health budgets of
industrialized countries. The postthrombotic syndrome (PTS) is defined by subjective symptoms and
morphologic trophical skin changes following deep venous thrombosis. Prevention of venous thromboem-
bolism in risk situations, easy availability of diagnostic tools (D-dimers, colour-coded duplex sonography)
and early detection of deep venous thrombosis, as well as immediate therapeutic anticoagulation along
with leg compression during the acute phase and over a two year period of time significantly reduce the
incidence of PTS. Chronic venous insufficiency (CVI) includes trophical skin and soft tissue pathologies
of the lower leg due to venous hypertension in the distal venous system of the lower extremity. Roughly,
two main causes can be distinguished. (A) Deep venous insufficiency (A1 in postthrombotic syndrome;
A2 in primary deep venous insufficiency) and (B) superficial venous reflux, usually varicose veins. Com-
pression therapy, surgical ablation of superficial venous reflux, and tangential ablation with split skin
graft (shave treatment) of refractory venous ulcers are the mainstays in the treatment of CVI.
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STUDY
Martorell Hypertensive Ischemic Leg Ulcer
A Model of Ischemic Subcutaneous Arteriolosclerosis
Jürg Hafner, MD; Stephan Nobbe, MD; Hugo Partsch, MD; Severin Läuchli, MD; Dieter Mayer, MD;
Beatrice Amann-Vesti, MD; Ruedi Speich, MD; Christoph Schmid, MD; Günter Burg, MD; Lars E. French, MD
Objectives: To better define the diagnosis and treat-
ment of Martorell hypertensive ischemic leg ulcer
(HYTILU) and to compare Martorell HYTILU with cal-
ciphylaxis (calcific uremic arteriolopathy) and non-
uremic forms of calciphylaxis.
Design: Retrospective study from 1999 through 2007.
Setting: Department of Dermatology, University Hos-
pital of Zurich, Zurich, Switzerland.
Participants: Of 330 patients with leg ulcers, 31 had a
clinical diagnosis ofMartorell HYTILU confirmed by der-
matopathologic examination.
Main Outcome Measures: Clinical features, sus-
pected diagnosis at initial presentation, cardiovascular
risk factors, findings from vascular examination and his-
tologic analysis, specific medical and surgical manage-
ment, and outcome.
Results:Of the 31 patients, all presented with 1 or mul-
tiple painful necrotic skin ulcers on the laterodorsal part
of the leg, with bilateral involvement in 16 of 31 cases
(52%), and 16 were referred with suspected pyoderma
gangrenosum. All patients had arterial hypertension, and
18 (58%) had diabetes. All patients had subcutaneous ste-
notic arteriolosclerosis on histologic analysis, with me-
dial calcification in 22 of 31 of cases (71%). Martorell
HYTILU, calciphylaxis, and nonuremic forms of calci-
phylaxis shared identical histologic features. Of the 31
patients, 29 (94%) were successfully treated with surgi-
cal debridement and split-thickness skin grafting. Three
patients (9%) died of sepsis, 2 of whom were undergo-
ing immunosuppressive treatment for wrongly diag-
nosed pyoderma gangrenosum.
Conclusions: Ischemic subcutaneous arteriolosclero-
sis is the hallmark of Martorell HYTILU, calciphylaxis,
and the nonuremic forms of calciphylaxis. All patients
are hypertensive and approximately 60%are diabetic.Mar-
torell HYTILU can easily be confusedwith pyoderma gan-
grenosum, which can be detrimental, since the 2 dis-
eases require a completely different treatment strategy.
Arch Dermatol. 2010;146(9):961-968
M ARTORELL HYPERTEN-sive ischemic leg ulcer(HYTILU) was origi-nally described byFernandesMartorell in
1945 in Barcelona, Spain.1 Martorell de-
scribed 4 obese, hypertensive female pa-
tients with painful leg ulcers on the lateral
aspectof their legs.Oneyear later,Hines and
Farber and coworkers2,3 reported an asso-
ciation of such leg ulcers with the histo-
logic presence of hypertrophic stenotic sub-
cutaneous arterioles and coined the term
hypertensive-ischemic ulcer. In1966, Schnier
et al4 reported a series of 40 patients with
HYTILU, pointing out the very character-
istic location of the principal lesion on the
laterodorsal lower leg. In1995,Lazarethand
Priollet5 described the benefit of skin graft-
ing for the treatment of l’angiodermite ne´cro-
tique, the term used by the French to de-
scribe HYTILU, which was confirmed by
Henderson et al6 in a survey on 16 patients.
The literature on HYTILU is otherwise
scarce,7 and to our knowledge, studies ana-
lyzing the clinical and dermatopathologic
characteristics and possible therapies on a
significant number of patients do not
exist.
At our department, Martorell HYTILU
has become one of the leading causes of
chronic leg ulceration in the past 10 years.
Martorell HYTILU shares striking clinical
and histopathological similarities with cal-
ciphylaxis (calcificuremicarteriolopathy)8-11
and eutrophication inmorbidobesity.12 The
latter has recently been referred to as “cal-
ciphylaxis with normal renal and parathy-
roid function”13 or “calciphylaxis fromnon-
uremic causes.”14 This studyof a large series
of patients withMartorell HYTILU defines
common pathophysiologic hallmarks of 4
entities that are linked to ischemic subcu-
taneous arteriolosclerosis (Table 1) and
outlines treatment protocols.
For editorial comment
see page 1026
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ConfusingMartorellHYTILUwithpyodermagangreno-
sum (PG) can be detrimental to the patient. Necrosec-
tomy (debridement of necrotic tissue), with skin grafting
and antibiotic therapy as required, is probably the key to
timely and effective treatment of Martorell HYTILU, but
an erroneous diagnosis of PG virtually excludes surgical
measures from the therapeutic decision.15
As noted byWeenig et al,16 one of the risks of misdiag-
nosing an inflammatory type of skin ulcer as PG is that the
systemic immunosuppressionused to treat PG exposes the
patients to the risk of sepsis.16 Therefore, this study also
aims to clarify the description of Martorell HYTILU and
PG to avoid misdiagnosis and therapeutic decisions.
METHODS
Medical records of 330 patients with leg ulcers who visited our
outpatient or inpatient department between 1999 and 2007were
screened for the diagnosis of Martorell HYTILU (Figure 1).
We identified 31 patients with both clinically and histologi-
cally proven HYTILU, whose files, clinical photodocumenta-
tion, and skin biopsy specimens were re-examined. During the
same period, 2 patients with calciphylaxis (calcific uremic ar-
teriolopathy) and 1 patient with eutrophication inmorbid obe-
sity (calciphylaxis with normal renal and parathyroid func-
tion) were treated in the department, and their records were
also re-evaluated in the present study. The study was submit-
ted to and approved by the local ethics committee.
DIAGNOSIS
Clinical characteristics thatwere studied included age, sex,wound
location, documentation of pain, diagnosis at the time of referral
(specifically PG), medication at the time of referral (specifically
antihypertensive or antidiabetic drugs and immunosuppression
for supposed PG), and cardiovascular risk factors.
Skin biopsy specimens derived from thewound border were
re-examined with a focus on the presence of subcutaneous ste-
notic arteriolosclerosis with or without medial calcification.
Vascular assessment comprised a thorough clinical exami-
nation, measurement of the ankle-brachial pressure index
(ABPI), segmental oscillography in case of medial calcinosis,
and, in the presence of pathologic findings, imaging via fine-
needle angiography.
To identify patients with end-stage renal disease (ESRD) or
kidney transplant recipients and hence patients with potential
calciphylaxis (calcific uremic arteriolopathy) or with a pri-
mary hyperparathyroidism, the records of all 31 included pa-
tients were checked for renal function and parathyroid hor-
mone and calciumphosphate product levels. The latter twowere
prospectively determined in the 16 patients who were in-
cluded in the study between 2005 and 2007.
TREATMENT
Our standardized treatment protocol for the management of
Martorell HYTILU is summarized in Figure 2. Basically, the
diagnosis is based on the typical history and clinical presenta-
tion and confirmed by obtaining a large wedge-shaped biopsy
specimen (approximately 5.00.8 cm, reaching the fascia) start-
ing from healthy skin at the wound border and extending into
the necrotic area. Immunosuppression for presumptive PGwas
stopped and antibiotic treatment initiated as required by the
general or local condition. In addition, necrosectomy using ad-
equate—usually tumescent—local anesthesia was under-
taken, local negative pressure treatmentwas started if thewound
bed still contained subvital tissue, and split-thickness skin graft-
ing (0.2-mm-thick, meshed graft) was then performed as soon
as possible.
RESULTS
CLINICAL ASSESSMENT
Of the 31 patients included, 19 (61%) were female, and
themean age of patientswas 72 years (range, 61-91 years).
The main clinical observation at presentation was skin
necrosis with a polycyclic violaceous-black border lo-
calized on the laterodorsal part of the leg (Figure 3),
with a surface area ranging from 2 to 242 cm2. Skin
necrosis involved the entire subcutis down to the fas-
cia. Sixteen patients (52%) had bilateral lower leg
necrosis, and the Achilles tendon was the principal
wound location in 4 of the 31 of patients (13%)
(Figure 4 and Table 2). Pain was typically strong to
excruciating. Seven patients (23%) reported a minor
trauma to be the initial trigger, whereas the remaining
persons reported a spontaneous onset presenting as a
violaceous macule or nodule.
All patients had arterial hypertension and were re-
ceiving antihypertensive treatment. It was not possible
to collect valid data on the history and duration of hy-
pertension because themajority of patients could not re-
call the year in which hypertensionwas diagnosed. How-
ever, several patients recalled taking antihypertensive
medications for more than 20 years. Of the 31 included
patients, 18 (58%) had documented type 2 diabetesmelli-
tus (Table 2) and 5 (16%) had a history of cigarette smok-
Table 1. Four Manifestations of Ischemic Arteriolosclerosis
Disease Distal Proximal
ESRD Calciphylaxis, distal pattern
Synonym: calcific uremic arteriolopathy
Distal: legs and forearms, toes and fingers, penis
Mortality: approximately 10%
Calciphylaxis, proximal pattern
Synonym: calcific uremic arteriolopathy
Proximal: trunk, thighs, upper arms
Mortality: approximately 50%-70%
Non-ESRD Martorell HYTILU
Synonym: angiodermite ne´crotique
Distal: laterodorsal leg or Achilles tendon
Mortality: approximately 10%
Nonuremic calciphylaxis
Synonym: calciphylaxis in normal renal and PTH
function or eutrophication in morbid obesity
Proximal: trunk, thighs, upper arms
Mortality: approximately 50%-70%
Abbreviations: approx, approximately; ESRD, end-stage renal disease; HYTILU, hypertensive ischemic leg ulcer; PTH, parathyroid hormone.
(REPRINTED) ARCH DERMATOL/VOL 146 (NO. 9), SEP 2010 WWW.ARCHDERMATOL.COM
962
©2010 American Medical Association. All rights reserved.
 at Hauptbibliothek Univ of Zurich, on September 26, 2010 www.archdermatol.comDownloaded from 
ing. Of the 25 patients in which lipid levels were re-
corded, 5 (20%) had elevated serum lipid levels, all of
whom were being treated with a statin.
DIAGNOSIS AT ENTRY
Of the 31 patients, 16 (52%) had a referral letter stating
PG as the suspected diagnosis. Of these 16 patients, 9
(56%) were unresponsive to high-dose systemic immu-
nosuppressive drugs, of whom 8 received treatment with
high-dose oral steroids associated with steroid-sparing
agents (cyclosporine [n=3], mycophenolate mofetil
[n=3], and intravenous cyclophosphamide pulses [n=2])
and 1 received cyclosporine monotherapy.
In another 6 patients (19%), necrotizing cutaneous leu-
kocytoclastic vasculitis was mentioned as the likely di-
agnosis. Three of these patients were treated with oral
steroids, resulting in a total of 12 patients (12 of 31 [39%])
taking immunosuppressive treatment at the time of
admission.
330 Consecutive patients with chronic leg and foot ulcers (1999-2007)
Clinical examination
Arterial examination with handheld Doppler US; calculation of ABPI
Venous examination with color-coded duplex US
254 Macrovascular ulcers (77%)
147 Venous
63 Venous superficial
55 Venous superficial/deep
29 Venous deep
59 Mixed venous-arterial
(venous and ABPI <0.9)
17 Arterial
(without arteriolosclerosis)
31 Martorell  HYTILU
(histologically arteriolosclerosis)
14 With PAD 
17 Without PAD
76 Other causes (23%)
25 Diabetic foot ulcers
8 Cases of rheumatoid arthritis
4 Cases of systemic sclerosis
8 Cases of immunocomplex vasculitis
4 Cases of pyoderma gangrenosum
2 Cases of necrobiosis lipoidica
4 Squamous cell carcinomas
3 Basal cell carcinomas
1 Kaposi sarcoma
2 Malignant lymphomas
2 Mixed bacterial infections
3 Cases of atypical mycobacteria
2 Cases of hydroxyurea
2 Cholesterol embolisms
2 Cases of calciphylaxis in chronic renal failure
2 Postradiotherapy complications
2 Blunt injuries
Figure 1. Study flowchart and etiologic distribution of 330 screened and treated patients. ABPI indicates ankle-brachial pressure index; HYTILU, hypertensive
ischemic leg ulcer; PAD, peripheral arterial disease; and US, ultrasonography.
? Stepwise increase of analgesic treatment
? Stop immunosuppression
? Intravenous antibiotic treatment, debridement
? Wedge-shaped skin biopsy to deep subcutis/fascia
B. First-line procedures
• Excruciating pain?
• Immunosuppression for supposed pyoderma gangrenosum?
• Lymphangitis/bacteremia/sepsis?
• Confirmation of diagnostic hypothesis
A. Clinical features at initial presentation
• Skin necrosis on laterodorsal aspect of the leg or on the Achilles tendon
• Arterial hypertension (100%)
• Metabolic syndrome, arterial hypertension, and type 2 diabetes (60%)
C. Second-line procedures
• Small wound area, little progression
• Large wound area, significant progression
? Sharp debridement, conservative local treatment
? Sharp debridement (spinal or general anesthesia)
? Negative pressure treatment until suitable wound ground
? Split-skin graft (0.2-mm thickness, meshed), rigorous 
infection control, antibiotics mostly required
D. Third-line procedures
• Wound closure of more than two-thirds, pain improved
• Wound closure of less than two-thirds, pain unchanged
? Conservative local treatment until complete healing
? Repeated split-thickness skin grafts
Figure 2. Decision model for the management of Martorell hypertensive ischemic leg ulcer.
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HISTOLOGIC CHARACTERISTICS
OF SKIN BIOPSY SPECIMENS
Re-examination of the histologic specimens revealed
stenotic arteriolosclerosis of the subcutaneous arteri-
oles with an inverse wall to lumen ratio (Figure 5).
In 22 of 31 patients (71%), medial calcinosis of the
subcutaneous arterioles was found to be an additional
characteristic feature (Figure 6B). Of these 22
patients, 14 (61%) with medial calcinosis of the sub-
cutaneous arterioles were diabetic, compared with 18
of all 31 patients (58%).
VASCULAR ASSESSMENT
Fourteen patients (45%) underwent pathologic arterial
screening examinations,withmedial calcinosis found in7
(50%).Peripheralarterialdisease(50%stenosis)wascon-
firmed inall 14patients, andall had lesions thatwere ame-
nable topercutaneous transluminal angioplasty (Table2).
Mönckeberg medial calcinosis with incompressible
ankle arteries was documented in 11 of 31 cases (35%).
Of these 11 patients, 4 (36%) with incompressible ankle
arteries had normal oscillography and, therefore, no fur-
ther investigations, whereas the remaining 7 (64%) un-
derwent angiography.
RENAL FUNCTION, PARATHYROID HORMONE,
AND CALCIUM PHOSPHATE PRODUCT
None of the 31 patients withMartorell HYTILU had end-
stage chronic renal failure, and none were kidney trans-
plant recipients. Creatinine levels and glomerular filtra-
tion rates were normal in 25 of 31 patients (84%) and
slightly or moderately impaired (creatinine level, 1.38-
1.60 mg/dL [reference range, 0.79-1.19 mg/dL] [to con-
vert to micromoles per liter, multiply by 88.4], and glo-
merular filtration rate, 34-52 mL/min [reference range,
60 mL/min]) in the remaining 5 (16%).
Among 16 of 31 included patients (52%), parathy-
roid hormone level was slightly raised (72.1-100.8 pg/
mL; reference range, 15-65 pg/mL [to convert to nano-
grams per liter, multiply by 1.0]) in 6 (38%), of whom 4
had normal renal function and 2 had slightly impaired
renal function. In all 16 patients, calciumphosphate prod-
uct level was normal.
SURGICAL MANAGEMENT
In only 2 of the 31patients (6%),woundswere healedwith
conservative treatment. The remaining patients had refrac-
torywounds, or evenprogressive skin necrosis. All of these
Figure 3. Clinical features of Martorell hypertensive ischemic leg ulcer
(HYTILU) located at the laterodorsal lower leg include skin infarction with
central necrosis and progressive inflammatory border. Excruciating pain is
typical. The clinical appearance of Martorell HYTILU is often confused with
pyoderma gangrenosum or with vasculitis.
Figure 4. In approximately 15% of patients, the Achilles tendon can be the
next most common location of hypertensive ischemic leg ulcer (HYTILU).
When skin necrosis is the only manifestation of Martorell HYTILU, the skin
necrosis may be misinterpreted as necrotizing friction blister from footwear.
Table 2. Clinical Features of Martorell Hypertensive
Ischemic Leg Ulcer
Clinical Feature
Patients, No. (%)
(n=31)
Hypertension (cardiovascular risk factor I) 31 (100)
Diabetes, type 2 diabetes mellitus (cardiovascular risk
factor II)
18 (58)
Location: laterodorsal leg 31 (100)
Bilateral occurrence, often separate onset 16 (52)
Histologic feature: arteriolosclerosis 31 (100)
Histologic feature: medial calcinosis 22 (71)
Peripheral arterial disease, confirmed by arteriogram 14 (45)
Initial misdiagnosis as pyoderma gangrenosum 16 (52)
Systemic immunosuppression for assumed pyoderma
gangrenosum (n=9) and assumed cutaneous
leukocytoclastic vasculitis (n=3)
12 (39)
Fatal outcome due to sepsis (2 of 3 patients were
immunosuppressed)
3 (9)
Healed with debridement and split-thickness skin graft
(12 of 26 patients had repeated operations)
26 (85)
Healed without surgery 2 (6)
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patients underwent repeated bedside debridement with a
disposable ring curette and local anesthesiawithEMLA(eu-
tectic mixture of lidocaine and prilocaine) cream, or they
underwent sharpnecrosectomy in theoperating room,usu-
allywith tumescent local anesthesia and some required spi-
nal or general anesthesia. Vacuum-assisted negative pres-
sure local wound care was used in 18 patients (58%).
Twenty-six patients (85%) received autologous split-
thickness skin grafts, ofwhom14 (54%)were grafted once;
7 (27%), twice; and 4 (15%), 3 times; and 1 required 6 suc-
cessive skin grafting procedures.
OUTCOME
By the end of the study, 28 patients (91%) survived and
finished the treatment protocol with completely healed
wounds. Three patients (9%), all of whom had extensive
skin necrosis and 2 of whom had received immunosup-
pressive therapy for supposedPG, died of sepsis during the
active phase of disease.
PAIN MANAGEMENT
All patients reported strong or even excruciating pain at
study entry (8-10 on a visual analog scale ranging from 0
to 10). The multistaged medical treatment of pain con-
sisted sequentiallyofnonsteroidal anti-inflammatorydrugs
(particularly paracetamol and metamizol), oral or trans-
cutaneous morphine derivatives, tricyclic antidepressive
agents, and pregabalin. Patients who did not respond ad-
equately to this regimen within 5 days of onset were re-
ferred to the pain control unit of the department of anes-
thesiology. Skingraftingwasby far the singlemost effective
treatment for pain.
COMMENT
On the basis of our case series and review of the medical
literature,1-14 we suggest grouping the 4 medical condi-
tions with ischemic subcutaneous arteriolosclerosis as a
Figure 5. A skin biopsy specimen from the wound edge of a hypertensive
ischemic leg ulcer. The asterisk indicates a subcutaneous arteriole with
extensive smooth muscle hyperplasia at the price of a narrowed lumen
(increased wall to lumen ratio) (hematoxylin-eosin, original magnification4).
B
A
C
B
C
Figure 6. A large 5.0  0.8-cm spindle-shaped biopsy specimen from
healthy-looking skin and skin leading into the wound. Many physicians do
not dare to perform such a large biopsy but rather take a punch biopsy from
the necrotic wound ground. The figure shows an overview of a cross section
of the necrotic border of a Martorell hypertensive ischemic leg ulcer
(HYTILU) (A) (hematoxylin-eosin, original magnification 10). Ironically,
when taking a punch biopsy from the wound ground of a Martorell HYTILU,
one will find a dense neutrophil infiltrate in a necrotic dermis (B)
(hematoxylin-eosin, original magnification 40). In other words, a
superficial wound biopsy can imitate the diagnosis of pyoderma
gangrenosum at a histologic level and confirm the erroneous suspicion of
pyoderma gangrenosum. A clinician, unaware of the existence of Martorell
HYTILU, could perform a superficial wound biopsy and receive a histologic
confirmation of pyoderma gangrenosum. If the clinician were to perform a
long, narrow, and deep biopsy down to fascia, he or she would find the
highly characteristic stenotic arterioles in the subcutis (C)
(hematoxylin-eosin, original magnification 40).
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common pathophysiologic feature as follows: (1) Mar-
torell HYTILU1-7; (2 and 3) calciphylaxis (calcific ure-
mic arteriolopathy)8-11 in its distal andmore serious proxi-
mal pattern; and (4) nonuremic calciphylaxiswith normal
renal and parathyroid function (eutrophication in mor-
bid obesity)12-14 (Table 1). This characteristic arteriolar
pathologic feature represents the most peripheral type
of atherosclerosis and seems to be associated with 2 ma-
jor cardiovascular risk factors often present in patients
withMartorell HYTILU, namely long-standing arterial hy-
pertension (in 100% of cases) and diabetes (frequent).
Martorell HYTILU represents the distal pattern of non-
uremic calciphylaxis.1-7 Clinically, it is defined by a rap-
idly progressive, extremely painful eschar on the lat-
erodorsal side of the leg or on the Achilles tendon.
Hypertension and histologically proven subcutaneous ar-
teriolosclerosis (showing medial calcinosis in 70% of
specimens) are mandatory to make the diagnosis. The
mortality in our series was 9%, and immunosuppres-
sionmay contribute to increase the risk of potentially fa-
tal septicemia.
Eutrophication12 represents the proximal pattern of
nonuremic calciphylaxis.13,14 Clinically, it is defined by
extensive, rapidly progressive and extremely painful es-
char formation on the trunk and proximal extremities,
particularly on the proximal and inner portion of the
thighs, on the abdomen, and on the breasts.12-14 Bothmac-
roscopically and microscopically, eutrophication can-
not be distinguished from calciphylaxis of the proximal
pattern.9 Case reports of eutrophication describe severe
comorbid disease, cancer, and liver cirrhosis.13,14 How-
ever, we hypothesize that hypertension and diabetes,
which both are regularly found in the context of meta-
bolic syndrome and morbid obesity, may be the driving
forces behind calciphylaxis of nonuremic origin. Eutro-
phication in morbid obesity has been reported to have a
mortality of approximately 40% to 60%,12-14 which is com-
parable to the proximal pattern of calciphylaxis.8,9
In calciphylaxis, an elevated calcium phosphate prod-
uct level due to secondary hyperparathyroidism has been
proposed to be involved in the pathogenesis.8-11 There is
good clinical evidence that an elevated calcium phos-
phate product level increases the risk for cardiovascular
events.17-20 By analogy, itwould appear probable that it also
enhances subcutaneous arteriolosclerosis, but this is not
easy to prove. Not all ESRDpatientswith calciphylaxis ex-
hibit secondary hyperparathyroidism, and parathyroidec-
tomy does not result in clinical improvement in all cases.9
Thematrix proteinGLA (serumprotein2–Heremans-
Schmid glycoprotein/fetuin A) is an effective vascular and
tissue protector against calcification.21-24 Future studies
on the aforementioned 4 arteriolosclerosis entities will
hopefully investigate the role of this protein in disease
pathogenesis. Matrix GLA requires vitamin K–depen-
dent -carboxylation to become active, whichwould sup-
port the impression of several authors that the condi-
tion of patients with calciphylaxis may deteriorate when
they are placed on warfarin therapy.11
Martorell HYTILU is certainlymore common than di-
agnosed and reported in the literature (3 case series in
the literature from 1966-1995).4-6 In our series, 50% of
patients withMartorell HYTILUwere admitted under the
referral diagnosis of PG and another 20% under the di-
agnosis of necrotizing vasculitis. In the literature, there
are a considerable number of cases that indeed could rep-
resent Martorell HYTILU instead of “leg ulcers in calci-
nosis cutis”25 or,more commonly, PG.26-29Moreover, case
series reporting the successful surgical management of
PG by skin grafts should probably be revisited taking into
consideration Martorell HYTILU.26-29
ConfusingMartorell HYTILUwith entities such as PG
or vasculitis can be deleterious,16 since management of
the latter 2 diseases is completely different (Table 3).
Martorell HYTILU requires anti-infectious treatment and
wound surgery, and immunosuppression may expose
these patients to an increased risk of septicemia. Mar-
torell HYTILU is an extremely painful eschar that usu-
ally occurs on the laterodorsal side of the leg in hyper-
tensive patients aged 60 to 75 years, whereas PG presents
as more superficial pustular skin breakdown with a less
precise location and 50% of patients have one of the char-
acteristically associated diseases such as inflammatory
bowel disease. Histologic proof of subcutaneous arterio-
losclerosis (Figure 5 and Figure 6A and B) is warranted
before making the diagnosis of Martorell HYTILU. Since
the results from superficial wound biopsies (“punch” bi-
opsies) can be totallymisleading, special attention should
be paid to the quality of the biopsy specimen (long, nar-
row, and deep elliptical biopsy specimen from healthy-
looking skin to necrotic skin) (Figure 6).
The wound border in Martorell HYTILU is strikingly
inflammatory, so that the existing confusion with PG is
to some extent understandable. As with PG, serological
parameters ofMartorell HYTILU, such as C-reactive pro-
tein level and leukocyte counts, can also be markedly el-
evated during the active phase of disease progression.Mar-
torell HYTILU is initially an atherosclerotic vascular
process, and the observed inflammatory response is sec-
ondary to the tissue breakdown resulting from local is-
chemia. The exact cause and pathomechanism of the in-
flammatory bursts that can be observed during disease
progression in Martorell HYTILU are unknown and
should be further investigated in future studies.
Duncan and Faris30 compared the skin perfusion of
patients with Martorell HYTILU to that of patients with
peripheral arterial disease and normal controls, using a
scintigraphic method measuring the elimination of in-
tradermally injected technetiumTc 99munder standard-
ized external compression. Patients with Martorell
HYTILU had reduced skin perfusion pressure compa-
rable to that in peripheral arterial disease, which was
caused by the locally increased vascular resistance in-
stead of a reduced arterial inflow.
Primary (“essential”) arterial hypertension is mainly
the result of increased peripheral vascular resistance,
which is essentially regulated via the tonus of arteri-
oles.31 Long-standing arteriolar vasoconstriction can lead
to a fixed increase in vessel wall thickness and an in-
verse wall to lumen ratio (“athletic” arterioles as de-
scribed byHines and Farber and colleagues2,3) (Figure 5).
The specificity of this finding for the diagnosis of Mar-
torell HYTILU has not been defined. This could be done
by a comparative study on cadaveric skin of the laterodor-
sal leg of a control group of patients.
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Some authors believe that arteriole thrombosis is a de-
cisive criterion for making a diagnosis of ischemic arte-
riolosclerosis, particularly in calciphylaxis7,8 We cannot
confirm this hypothesis, since approximately half of the
arterioles examined in our specimens were patent. Ar-
teriole thrombosis can occur either primarily or subse-
quent to tissue breakdown, and the two cannot be dis-
tinguished by histopathologic analysis. However, this
question could be addressed in future studies using se-
rial sections of the wound border of larger necrosec-
tomy specimens.
The characteristic location of Martorell HYTILU on
the laterodorsal side of the leg or the Achilles tendon4 is
not explained to date, but it is most probably related to
the anatomy of calf arteries, arterial perforators, and the
distribution of subcutaneous arterioles in the leg. Cor-
rosion preparations of amputated limbs of patients with
known subcutaneous arteriolosclerosis or postmortem
investigations could be helpful in addressing these open
questions.
Recent reports promise progress in both conserva-
tive and surgical treatment of uremic andnonuremic forms
of ischemic arteriolosclerosis. The introduction of the cal-
cimimetic cinecalcet32 and of the polymeric (and calcium-
free) intestinal phosphate binder sevelamer33 seem to have
a beneficial effect on the incidence ofmacrovascular events
in patientswith relevantmedium-size artery (such as coro-
nary artery) calcification. Cinecalcet has at least been used
twice successfully to treat patients with calciphylaxis11;
however, these promising reports need to be validated
in larger series of patients or, ideally, controlled studies.
Of even more interest is the intravenous use of sodium
thiosulfate for classic calciphylaxis34 as well as non-
uremic forms of calciphylaxis.35 The beneficial effect of
sodium thiosulfate is ascribed to its potential to dissolve
already precipitated calcium salts in the vessels and tis-
sues.34,35 Empirically, it has been administered 3 times
perweek intravenously, eg, before dialysis in patientswith
ESRD. It causes extensive metabolic acidosis and there-
fore requires specialized monitoring and equipment.
Adequate therapeutic control of hypertension does not
appear to be sufficient for the treatment of Martorell
HYTILU. All our patients with newly diagnosed Mar-
torell HYTILU were receiving adequate antihyperten-
sive treatment on admission. It seems that the active pro-
cess of Martorell HYTILU cannot be stopped or reversed
with intensifiedmedical antihypertensive treatment alone.
Future epidemiologic studies may answer the question
as to howwell optimal antihypertensive control overmany
years may prevent the occurrence of Martorell HYTILU.
The incidence ofMartorell HYTILUmay be on the rise
owing to better recognition, an actual increase in inci-
dence, or both. We hypothesize that improved antihy-
pertensive treatment helps to extend a patient’s life ex-
pectancy and decreases the rate of death due to major
cardiovascular complications early in life, specificallymyo-
cardial infarction and stroke, which may have contrib-
uted to the apparent increase in frequency of Martorell
HYTILU. Martorell HYTILU may thus be understood as
late “minor” vascular complication of long-standing ar-
terial hypertension in a population that benefits from im-
proved antihypertensive treatment.
Ischemic arteriolosclerosis appears tobe aunifying clini-
copathological concept for 4 clinical entities that share a
common pathophysiologic mechanism, namely (1) dis-
tal calciphylaxis (uremic); (2) distal Martorell HYTILU
(nonuremic); (3) proximal calciphylaxis (uremic); and (4)
eutrophication inmorbid obesity or proximal nonuremic
calciphylaxis.We suggest that ischemic subcutaneous ar-
teriolosclerosis may be caused by 2 well-established clas-
Table 3. Martorell HYTILU, Calciphylaxis, Nonuremic Calciphylaxis, and Pyoderma Gangrenosum
Feature Martorell HYTILU Calciphylaxis Nonuremic Calciphylaxis
Pyoderma
Gangrenosum
Hypertension 100% By definition 100% 100% Possible, not related
Diabetes 60% Frequency in this
series
Diabetic nephropathy Type 2 diabetes very
frequent
Possible, not related
Morbid obesity Frequent Possible, not related 100% By definition Possible, not related
Kidney disease No 100% By definition No Rarely, not related
Inflammatory bowel disease
or hematoproliferative
disease
Rarely, not related Rarely, not related Rarely, not related 50%
Histologic feature
Subcutaneous
arteriolosclerosis
100% By definition 100% By definition 100% No
Dense neutrophilic
infiltrates
Yes, caution with a
superficial biopsy
Yes, caution with a
superficial biopsy
Yes, caution with a
superficial biopsy
Yes
Location Laterodorsal leg,
Achilles tendon
Acral, distal and proximal
but not head
Proximal skin Any location
Systemic treatment Antihypertensive,
control of diabetes
Support kidney function,
lower phosphate level,
discuss sodium
thiosulfate
Antihypertensive,
control of diabetes,
weight loss, discuss
sodium thiosulfate
Immunosuppression
Local treatment Debride necrotic material
and split-thickness skin
graft
Debride necrotic material
and split-thickness skin
graft
Debride necrotic material
and split-thickness skin
graft
Surgery is
contraindicated
Abbreviations: HYTILU, hypertensive ischemic leg ulcer; PTH, parathyroid hormone.
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sic cardiovascular risk factors: long-standing arterial hy-
pertension and diabetes. For disease management, it is of
utmost importance that these diseases are not confused
with PG or necrotizing vasculitis because their treatment
is completely different (namely surgical), and exposing pa-
tients with tissue necrosis due to ischemic arterioloscle-
rosis to systemic immunosuppression may raise the risk
of septicemia.
Future studies should address the role of the calcifica-
tion protective matrix protein GLA, as well as the cyto-
kine pattern during the inflammatory phase of progres-
sive tissuebreakdownthat characterizes theaforementioned
diseases causing ischemic arteriolosclerosis and skin le-
sions. Furthermore,morphological questions regarding the
vascular pathologic mechanisms (eg, the role of calcifica-
tion, intimal hyperplasia, and thrombosis) and the pecu-
liar location of the skin necroses in Martorell HYTILU
should be further studied. Therapeutic studies may help
define the value of the nonsurgical approach using so-
diumthiosulfate comparedwith the surgical approachusing
early escharectomy and mesh grafting.
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